Welcome to our dedicated page for Royalty Pharma plc SEC filings (Ticker: RPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Royalty Pharma plc filings document the company’s biopharmaceutical royalty business, public equity structure, governance, financing activity, and material events. Form 8-K reports furnish quarterly and annual results, including Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, and developments affecting royalty and funding arrangements.
Regulation FD and material-agreement disclosures describe royalty transactions, synthetic royalty funding, senior secured loan arrangements, and portfolio-related clinical or regulatory events. Other filings cover Class A ordinary shares listed on Nasdaq, senior note issuances and related guarantees, annual meeting matters, board and compensation governance, shareholder voting items, and changes involving directors or officers.
TPC RP EPA1 LLC, an affiliate stockholder of Royalty Pharma plc (symbol RPRX), filed a notice of proposed sale of 11,002 shares of common stock through Goldman Sachs & Co. LLC. The shares were acquired on 08/05/2026 as compensation under performance awards from the issuer.
The filing also lists a prior transaction in the last three months, where TPC RP EPA1 LLC sold 64,399 shares of common stock on 05/26/2026 for an aggregate amount of $3,476,118.96.
Royalty Pharma plc (ticker RPRX) filed notice of a proposed sale of up to 11,925,082 Class A ordinary shares through J.P. Morgan Securities LLC on NASDAQ. The shares were acquired over time, including 125,000 shares from a Conversion of LP Interests on August 7, 2026 and multiple smaller grants received as compensation from the issuer between June 30, 2021 and May 13, 2026.
A shareholder of RPRX filed to potentially sell 125,000 Class A ordinary shares through broker J.P. Morgan Securities LLC on or after August 12, 2026, listed on NASDAQ. The filing notes the planned sale relates to a Conversion of LP Interests dated August 7, 2026.
The shares have an indicated aggregate market value of 7,223,750, while the issuer reports 445,277,344 Class A ordinary shares outstanding. This notice outlines an intention to sell; it does not confirm that any sale has occurred.
Pablo G. Legorreta, CEO and Chairman of Royalty Pharma, reported an exempt award of 65,216 Class A Ordinary Shares in settlement of Equity Performance Awards, bringing his direct Class A stake to 1,307,820 shares. He also made a bona fide gift of 30,000 LP interests in RPI US Partners 2019, LP, representing 300,000 underlying Class A shares; these limited partnership interests may be exchanged into Class A at no additional cost under an exchange agreement. The filing also notes substantial indirect holdings through family entities and trusts, including 9,700,000 Class B and 13,356,742 Class E shares that are exchangeable into Class A, with Class E subject to vesting conditions.
Royalty Pharma plc EVP & CFO Terrance P. Coyne reported two equity changes. On August 5, 2026, an exempt acquisition under Rule 16b-3 delivered 11,002 Class A Ordinary Shares through settlement of Equity Performance Awards to TPC RP EPA1 LLC. On August 7, 2026, an indirect bona fide gift transferred 18,500 Class E Ordinary Shares, leaving 1,788,777 Class E shares indirectly held; these Class E shares are subject to vesting and are ultimately convertible into Class A Ordinary Shares. Coyne and related vehicles also hold limited partnership interests exchangeable into 6,448,180 Class A Ordinary Shares, plus additional direct and indirect Class A positions.
Hite Christopher reported acquisition or exercise transactions in this Form 4 filing.
Royalty Pharma plc executive Christopher Hite, EVP & Chairman, Partnering, received an exempt grant of 11,002 Class A Ordinary Shares on 2026-08-05 in connection with settlement of Equity Performance Awards, held indirectly through SCH Investment Partners LLC, bringing that entity’s holdings to 470,401 shares. He also holds 40,000 Class A Ordinary Shares directly, while family vehicles controlled by him hold limited partnership interests exchangeable into 866,410 additional Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 1,238,789 Class A Ordinary Shares, which are subject to vesting conditions.
Royalty Pharma plc executive Urist Marshall reported two insider equity movements. He received 8,252 Class A Ordinary Shares as an exempt award tied to Equity Performance Awards and indirectly made a bona fide gift of 3,000 limited partnership interests exchangeable into 30,000 Class A shares. He also holds Class A shares indirectly through an IRA and Class E Ordinary Shares that are exchangeable into 1,356,528 Class A shares, subject to vesting conditions.
Royalty Pharma plc reported total income and other revenues of $674,141 thousand for the quarter and $1,304,717 thousand for the six months ended June 30, 2026, driven mainly by income from financial royalty assets. Six‑month net income attributable to Royalty Pharma plc increased to $312,572 thousand from $271,525 thousand, with basic and diluted EPS of $0.71.
Operating cash flow for the first half rose to $1,446,694 thousand, while $707,587 thousand was used in investing activities, largely for $703,387 thousand of acquisitions of financial royalty assets. Cash and cash equivalents were $811,986 thousand against total debt of $8,961,892 thousand. Financial royalty assets, net, were $17,082,171 thousand. Results reflected a $69,443 thousand impairment on the Tazverik royalty, higher R&D funding expense of $137,641 thousand, and $229,648 thousand of share‑based compensation tied to the 2025 internalization. Shareholder returns included two $0.235 per‑share dividends totaling $209,406 thousand and repurchase of 2.0 million Class A shares for approximately $95.6 million.
Royalty Pharma plc reported second quarter 2026 results and raised full-year 2026 guidance for Portfolio Receipts. Portfolio Receipts were $773 million, up 6%, and Royalty Receipts were $768 million, up 14%, driven by Tremfya, Voranigo, Imdelltra and Evrysdi. Net cash provided by operating activities doubled to $728 million. Adjusted EBITDA and Portfolio Cash Flow each reached $736 million, reflecting payments for operating and professional costs at 4.8% of Portfolio Receipts.
The company now expects 2026 Portfolio Receipts of $3,400 million to $3,500 million, versus $3,325 million to $3,450 million previously, implying expected Royalty Receipts growth of 7% to 10%. Cash and cash equivalents were $812 million and total debt principal was $9.2 billion as of June 30, 2026; a $380 million term loan was repaid in July. Capital Deployment was $349 million in the quarter, including royalty funding for daraxonrasib and R&D funding for JNJ‑4804 and litifilimab. Net income attributable to Royalty Pharma plc was $18 million compared with $32 million a year earlier.
Royalty Pharma plc EVP of Research & Investments Marshall Urist reported an open-market sale of 9,099 Class A Ordinary Shares. The shares were sold on July 1, 2026 at a weighted average price of $55.8802 per share in multiple trades within a disclosed price range. The filing states that all reported transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026. After this sale, Urist reports no directly held Class A shares and an indirect holding of 19,020 shares through an IRA.